NeOnc Technologies announces Executive Chairman interview on July 24, 2025, discussing recent partnership and clinical developments.
Quiver AI Summary
NeOnc Technologies Holdings, Inc. announced that its Executive Chairman, Amir Heshmatpour, will participate in a live interview with financial commentator Kenny Polcari on July 24, 2025, at 11:00 a.m. ET on YouTube. This event follows NeOnc’s recent Sub-License Agreement with its subsidiary, NuroCure, aimed at advancing a $50 million partnership with Quazar Investment. The agreement will facilitate NeOnc’s expansion in the UAE and MENA regions, reflecting the company's dedication to developing therapies for brain and central nervous system cancers. Additionally, NeOnc's inclusion in the Russell Microcap Index supports its efforts to attract institutional investment. Heshmatpour expressed excitement about the company's trajectory and the chance to share its achievements. NeOnc’s innovative drug development platform currently includes therapeutics in clinical trials with promising results for cancer treatment.
Potential Positives
- NeOnc Technologies' Executive Chairman will be featured in a live interview, enhancing the company's visibility and engagement with potential investors and stakeholders.
- The recent execution of a Sub-License Agreement with its Abu Dhabi subsidiary is a significant step toward a $50 million strategic partnership, indicating strong business development and potential revenue growth.
- NeOnc's inclusion in the Russell Microcap Index aligns with its goal to attract institutional capital and enhance market liquidity, which can positively impact its stock performance and investor interest.
- The company's innovative NEO™ drug development platform continues to show promise with ongoing clinical trials for NEO100™ and NEO212™, reflecting its commitment to advancing treatment options for brain cancers.
Potential Negatives
- The press release contained a critical error regarding the date, which could undermine the company's credibility and attention to detail.
- The mention of a reliance on forward-looking statements emphasizes uncertainty about the company's future agreements and performance, potentially raising concerns among investors.
- The press release discusses ongoing clinical trials, which implies there are no guarantees of success, leaving the company exposed to potential setbacks that could affect investor confidence.
FAQ
What is the date and time of the live interview?
The live interview will take place on July 24, 2025, at 11:00 a.m. ET.
Who will be interviewing NeOnc Technologies' Executive Chairman?
The Executive Chairman, Amir Heshmatpour, will be interviewed by financial commentator Kenny Polcari.
What recent milestone has NeOnc Technologies achieved?
NeOnc Technologies executed a Sub-License Agreement with its subsidiary, NuroCure, as part of a $50 million partnership with Quazar Investment.
What does NeOnc Technologies focus on?
NeOnc Technologies is focused on developing treatments for brain and central nervous system cancers using its NEO™ drug development platform.
How can I learn more about NeOnc Technologies?
You can visit NeOnc Technologies' official website at neonc.com for more information about their technology and updates.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
margin: 24px 0;
padding: 20px;
background: linear-gradient(90deg, #c6a3f7 0%, #a8bde3 50%, #7bd4bb 100%);
border: 1px solid #c5e1a5;
border-radius: 10px;
box-shadow: 0 2px 6px rgba(0,0,0,0.08);
text-align: center;
font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif;
display: none;
">
Receive $NTHI Data Alerts
Sign Up
$NTHI Insider Trading Activity
$NTHI insiders have traded $NTHI stock on the open market 16 times in the past 6 months. Of those trades, 16 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NTHI stock by insiders over the last 6 months:
- AMIR F HESHMATPOUR (President) has made 7 purchases buying 12,000 shares for an estimated $121,299 and 0 sales.
- THOMAS C CHEN (CEO) has made 3 purchases buying 5,868 shares for an estimated $42,802 and 0 sales.
- JIM DELSHAD has made 3 purchases buying 5,100 shares for an estimated $37,258 and 0 sales.
- KEITHLY GARNETT (CFO) has made 3 purchases buying 900 shares for an estimated $6,527 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Full Release
CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- In a press release issued earlier today by NeOnc Technologies Holdings, Inc. under the headline, "NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET," please note "today" in the headline and first paragraph should be "July 24, 2025." The corrected release follows:
NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — July 24, 2025 at 11:00 a.m. ET
NeOnc Technologies Holdings, Inc. (
NTHI
), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, is pleased to announce that its Executive Chairman & President, Amir Heshmatpour, will be featured in a live interview with prominent financial commentator Kenny Polcari on
YouTube.com/@Floorstocks
. The interview will air
live July 24, 2025 at 11:00 a.m. ET
.
The interview comes on the heels of NeOnc’s recent execution of a Sub-License Agreement with its Abu Dhabi onshore operating subsidiary, NuroCure, a key milestone toward the company’s $50 million strategic partnership with Quazar Investment. This agreement, which covers the UAE and the broader GCC and MENA regions, reflects NeOnc’s commitment to expanding its footprint and delivering life-saving therapies to patients worldwide.
NeOnc was also recently included in the Russell Microcap Index, a milestone that aligns with the company’s broader capital markets strategy to attract institutional capital, drive passive fund flows, and enhance market liquidity.
“This is an exciting time for NeOnc Technologies as we move closer to closing the $50 million partnership with Quazar Investment and advancing our mission to transform the treatment of brain cancers,” said Amir Heshmatpour, Executive Chairman & President of NeOnc Technologies Holdings, Inc. “We are honored to share our journey and achievements with Kenny Polcari’s and Floorstocks’ audiences.”
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
